Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Taisho Pharmaceutical Holdings Co stock price, quote, forecast and news

4581.T
JP3442850008
A1JKG0

Price

8,580.00
Today +/-
+0
Today %
+0 %
P

Taisho Pharmaceutical Holdings Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Taisho Pharmaceutical Holdings Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Taisho Pharmaceutical Holdings Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Taisho Pharmaceutical Holdings Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Taisho Pharmaceutical Holdings Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Taisho Pharmaceutical Holdings Co Stock Price History

DateTaisho Pharmaceutical Holdings Co Price
4/8/20248,580.00 undefined
4/5/20248,590.00 undefined

Taisho Pharmaceutical Holdings Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Taisho Pharmaceutical Holdings Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Taisho Pharmaceutical Holdings Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Taisho Pharmaceutical Holdings Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Taisho Pharmaceutical Holdings Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Taisho Pharmaceutical Holdings Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Taisho Pharmaceutical Holdings Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Taisho Pharmaceutical Holdings Co’s growth potential.

Taisho Pharmaceutical Holdings Co Revenue, EBIT and net profit per share

DateTaisho Pharmaceutical Holdings Co RevenueTaisho Pharmaceutical Holdings Co EBITTaisho Pharmaceutical Holdings Co Net Income
2027e297.64 B undefined0 undefined14.07 B undefined
2026e315.42 B undefined0 undefined14.44 B undefined
2025e329.51 B undefined23.43 T undefined18.28 B undefined
2024e324.97 B undefined23.03 T undefined11.97 B undefined
2023301.38 B undefined23.02 B undefined19 B undefined
2022268.2 B undefined10.74 B undefined13.12 B undefined
2021281.98 B undefined19.97 B undefined13.32 B undefined
2020288.53 B undefined21.14 B undefined20.17 B undefined
2019261.55 B undefined31.21 B undefined48.59 B undefined
2018280.09 B undefined36.98 B undefined31.68 B undefined
2017279.77 B undefined31.97 B undefined28.78 B undefined
2016290.14 B undefined28.88 B undefined22.47 B undefined
2015290.5 B undefined31.97 B undefined24.53 B undefined
2014295.96 B undefined41.68 B undefined32.69 B undefined
2013285.17 B undefined35.34 B undefined26.32 B undefined
2012271.23 B undefined38.41 B undefined24.36 B undefined

Taisho Pharmaceutical Holdings Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (T)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e
271.23285.17295.96290.5290.14279.77280.09261.55288.53281.98268.2301.38324.97329.51315.42297.64
-5.143.78-1.84-0.12-3.570.11-6.6210.31-2.27-4.8912.377.831.40-4.28-5.64
63.5061.8162.4061.3661.0063.7165.3165.1362.4362.3961.0959.01----
172.23176.26184.68178.26176.99178.25182.94170.35180.14175.93163.83177.850000
0.040.040.040.030.030.030.040.030.020.020.010.0223.0323.4300
14.1612.3914.0811.019.9511.4313.2011.937.337.084.017.647,086.247,111.10--
24.3626.3232.6924.5322.4728.7831.6848.5920.1713.3213.121911.9718.2814.4414.07
-8.0624.21-24.97-8.3828.0710.0753.39-58.49-33.99-1.4644.77-37.0052.73-21.00-2.60
----------------
----------------
82818181.1180.9679.9679.9579.8979.979.9181.5482.090000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Taisho Pharmaceutical Holdings Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Taisho Pharmaceutical Holdings Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
201220132014201520162017201820192020202120222023
                       
113.73131.73159.4169.63206.46201.28249.71358.47237.9254.2272.27256.17
78.4983.1878.0780.1575.1669.4575.1671.1365.0151.1853.2751.75
00000000000178
24.825.8327.1227.3126.6427.526.8429.5243.3746.3844.8953.33
17.7713.5916.451211.4210.724.4410.679.345.988.4414.46
234.78254.33281.05289.08319.67308.95356.16469.78355.62357.73378.86375.88
92.84100.92103.58100.3798.9597.2893.7291.28112.65113.19119.29141.17
245.28258.76279.93319.33291.8320.01302.09203.69157.48168.32153.62163.42
000000000000
21.1422.6325.7923.1519.8217.615.7711.7788.6487.9287.29110.44
17.7321.7522.9922.0919.0516.7715.3512.53133.17128.61125.77128.05
17.7418.0115.1114.089.7610.6116.5332.7217.4221.1523.3222.53
394.72422.06447.4479.01439.38462.28443.46352509.35519.19509.3565.61
629.5676.39728.44768.09759.05771.22799.62821.78864.97876.92888.16941.49
                       
303030303030303030303030
1515.2715.2715.2715.2715.2715.2714.9200.0100
550.61567.9591.76610623.61644.52667.49707.43699703.84703.74714.6
-11.08-6.01-1.852.37-7.71-8.36-6.96-2.76-4.191.089.8629.6
4.7516.0422.6440.05036.2337.9732.0220.830.0325.5933.43
589.27623.2657.81697.7661.18717.67743.77781.61745.6764.96769.18807.63
28.9928.3527.8629.1327.0823.3319.9418.8118.0514.6715.117
13.4713.5615.0414.5914.6813.8514.5613.4423.0818.9315.3718.43
20.8520.7132.9220.2224.7420.8125.4225.7723.5222.4729.5236.55
00.220.230.180.050.110.380.411.631.41.61.1
00001030023182187690690
63.3162.8376.0564.1266.6558.160.358.4566.4657.6762.2873.78
0000.350.25000.021.2911.210.8
4.4610.914.3919.5416.3316.1316.9713.5330.0432.7529.1632.8
23.0824.4926.0730.7332.731.9131.0325.6427.4127.127.5524.77
27.5335.440.4650.6249.2848.044839.1958.7460.8557.9358.37
90.8498.23116.51114.74115.92106.13108.397.65125.2118.52120.2132.15
680.11721.43774.32812.44777.1823.8852.07879.26870.8883.47889.39939.78
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Taisho Pharmaceutical Holdings Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Taisho Pharmaceutical Holdings Co's financial health and stability.

Assets

Taisho Pharmaceutical Holdings Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Taisho Pharmaceutical Holdings Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Taisho Pharmaceutical Holdings Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Taisho Pharmaceutical Holdings Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
42.9943.2151.3240.1635.8141.9648.0764.4830.3122.9821.429.5
12.0812.0512.3912.9412.4711.6711.3811.2916.722.0423.0724.65
000000000000
-25.5-7.025.74-10.91.29-3.29-8.61-23.744.42-0.15-5.84-7.78
-5,844-8,039-9,213-8,718-6,511-10,268-10,986-32,856-9,434-2,842-10,125-5,392
1117222122119173158173
16.848.457.0516.429.1811.3411.6814.9314.146.198.6910.21
23.7340.2160.2333.4843.0640.0739.8519.1841.9942.0328.5140.97
-11,239-12,681-14,860-5,764-8,214-8,830-5,013-4,914-9,121-14,372-14,389-50,379
-39.35-9.36-22-18.16-11.66-1.36-19.9166.04-107.08-1.96-7.06-27.13
-28.113.32-7.14-12.4-3.457.47-14.970.96-97.9612.417.3323.25
000000000000
-239-820-121-161-236-45-103-86-1,337-686-254-1,064
-15,079-61-110-97-10,097-100-96-341-48-41-43-34
-23,073-10,064-9,439-9,443-19,525-8,404-9,867-15,467-11,696-11,346-10,057-10,877
-330.00-325.00-314.00-285.00-289.00-285.00-897.00-6,267.00-725.00-1,832.00-2,345.00-1,573.00
-7,425-8,858-8,894-8,900-8,903-7,974-8,771-8,773-9,586-8,787-7,415-8,206
-39.1321.6530.026.911.2329.9510.1469.19-76.6128.4112.174.56
12,49227,52745,37327,71434,84231,23534,83814,26432,87227,65414,117-9,407
000000000000

Taisho Pharmaceutical Holdings Co stock margins

The Taisho Pharmaceutical Holdings Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Taisho Pharmaceutical Holdings Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Taisho Pharmaceutical Holdings Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Taisho Pharmaceutical Holdings Co's sales revenue. A higher gross margin percentage indicates that the Taisho Pharmaceutical Holdings Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Taisho Pharmaceutical Holdings Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Taisho Pharmaceutical Holdings Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Taisho Pharmaceutical Holdings Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Taisho Pharmaceutical Holdings Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Taisho Pharmaceutical Holdings Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Taisho Pharmaceutical Holdings Co Margin History

Taisho Pharmaceutical Holdings Co Gross marginTaisho Pharmaceutical Holdings Co Profit marginTaisho Pharmaceutical Holdings Co EBIT marginTaisho Pharmaceutical Holdings Co Profit margin
2027e59.01 %0 %4.73 %
2026e59.01 %0 %4.58 %
2025e59.01 %7,111.1 %5.55 %
2024e59.01 %7,086.24 %3.68 %
202359.01 %7.64 %6.3 %
202261.09 %4.01 %4.89 %
202162.39 %7.08 %4.72 %
202062.43 %7.33 %6.99 %
201965.13 %11.93 %18.58 %
201865.31 %13.2 %11.31 %
201763.71 %11.43 %10.29 %
201661 %9.95 %7.75 %
201561.36 %11.01 %8.44 %
201462.4 %14.08 %11.05 %
201361.81 %12.39 %9.23 %
201263.5 %14.16 %8.98 %

Taisho Pharmaceutical Holdings Co Stock Sales Revenue, EBIT, Earnings per Share

The Taisho Pharmaceutical Holdings Co earnings per share therefore indicates how much revenue Taisho Pharmaceutical Holdings Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taisho Pharmaceutical Holdings Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taisho Pharmaceutical Holdings Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taisho Pharmaceutical Holdings Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taisho Pharmaceutical Holdings Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taisho Pharmaceutical Holdings Co Revenue, EBIT and net profit per share

DateTaisho Pharmaceutical Holdings Co Sales per ShareTaisho Pharmaceutical Holdings Co EBIT per shareTaisho Pharmaceutical Holdings Co Earnings per Share
2027e3,631.18 undefined0 undefined171.59 undefined
2026e3,848.15 undefined0 undefined176.18 undefined
2025e4,020.04 undefined0 undefined223.01 undefined
2024e3,964.6 undefined0 undefined146.02 undefined
20233,671.44 undefined280.41 undefined231.42 undefined
20223,289.3 undefined131.75 undefined160.93 undefined
20213,528.85 undefined249.85 undefined166.64 undefined
20203,611.1 undefined264.54 undefined252.47 undefined
20193,273.85 undefined390.67 undefined608.24 undefined
20183,503.3 undefined462.5 undefined396.23 undefined
20173,498.96 undefined399.78 undefined359.95 undefined
20163,583.86 undefined356.71 undefined277.6 undefined
20153,581.62 undefined394.22 undefined302.41 undefined
20143,653.79 undefined514.6 undefined403.6 undefined
20133,520.59 undefined436.26 undefined324.94 undefined
20123,307.68 undefined468.45 undefined297.04 undefined

Taisho Pharmaceutical Holdings Co business model

Taisho Pharmaceutical Holdings Co Ltd is a leading Japanese pharmaceutical company specializing in the development and distribution of drugs and health products. The company is headquartered in Tokyo and has been active since its establishment in 1912. Taisho Pharmaceutical Holdings Co is one of the most popular companies on Eulerpool.com.

Taisho Pharmaceutical Holdings Co SWOT Analysis

Strengths

Taisho Pharmaceutical Holdings Co Ltd possesses several strengths that contribute to its success in the pharmaceutical industry:

  • Strong brand reputation and recognition in the market
  • Wide range of established and trusted product portfolio
  • Strong distribution network and global presence
  • Robust research and development capabilities
  • Continuous focus on innovation and new product development
  • Efficient supply chain management

Weaknesses

Despite its strengths, Taisho Pharmaceutical Holdings Co Ltd also faces certain weaknesses that need to be addressed:

  • Dominant presence in the Japanese market, limited international market penetration
  • Reliance on key products for revenue generation
  • Financial dependency on a specific customer or region
  • Need to strengthen partnerships and collaborations with other industry players
  • Challenges in adapting to rapidly changing regulatory environments

Opportunities

Taisho Pharmaceutical Holdings Co Ltd has several potential opportunities to capitalize on:

  • Expansion into emerging markets with increasing healthcare needs
  • Growth potential in over-the-counter (OTC) medicine segment
  • Investment in research and development of novel drugs and therapeutics
  • Strategic acquisitions or partnerships to enhance product portfolio
  • Increasing demand for health and wellness products

Threats

Taisho Pharmaceutical Holdings Co Ltd should be cautious of the following potential threats:

  • Intense competition within the pharmaceutical industry
  • Stringent regulatory requirements and compliance
  • Uncertainties in healthcare policies and reimbursement systems
  • Rapidly evolving technology and potential disruption of traditional business models
  • Risk of product recalls or quality control issues impacting reputation

Taisho Pharmaceutical Holdings Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Taisho Pharmaceutical Holdings Co historical P/E ratio, EBIT, and P/S ratio.

Taisho Pharmaceutical Holdings Co shares outstanding

The number of shares was Taisho Pharmaceutical Holdings Co in 2023 — This indicates how many shares 82.088 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taisho Pharmaceutical Holdings Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taisho Pharmaceutical Holdings Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taisho Pharmaceutical Holdings Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taisho Pharmaceutical Holdings Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taisho Pharmaceutical Holdings Co dividend history and estimates

In 2023, Taisho Pharmaceutical Holdings Co paid a dividend amounting to 100 JPY. Dividend means that Taisho Pharmaceutical Holdings Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Taisho Pharmaceutical Holdings Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Taisho Pharmaceutical Holdings Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Taisho Pharmaceutical Holdings Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Taisho Pharmaceutical Holdings Co Dividend History

DateTaisho Pharmaceutical Holdings Co Dividend
2027e100.73 undefined
2026e100.74 undefined
2025e100.72 undefined
2024e100.72 undefined
2023100 undefined
2022100 undefined
2021100 undefined
2020110 undefined
201960 undefined
2018110 undefined
2017110 undefined
2016100 undefined
2015110 undefined
2014110 undefined
2013110 undefined
2012110 undefined

Taisho Pharmaceutical Holdings Co dividend payout ratio

In 2023, Taisho Pharmaceutical Holdings Co had a payout ratio of 55.24%. The payout ratio indicates the percentage of the company's profits that Taisho Pharmaceutical Holdings Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Taisho Pharmaceutical Holdings Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Taisho Pharmaceutical Holdings Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Taisho Pharmaceutical Holdings Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Taisho Pharmaceutical Holdings Co Payout Ratio History

DateTaisho Pharmaceutical Holdings Co Payout ratio
2027e58.57 %
2026e57.74 %
2025e58.84 %
2024e59.13 %
202355.24 %
202262.14 %
202160.01 %
202043.57 %
20199.86 %
201827.76 %
201730.56 %
201636.02 %
201536.37 %
201427.25 %
201333.85 %
201237.03 %
Unfortunately, there are currently no price targets and forecasts available for Taisho Pharmaceutical Holdings Co.

Taisho Pharmaceutical Holdings Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/202382.55 35.04  (-57.55 %)2024 Q3
9/30/202361.66 37.66  (-38.92 %)2024 Q2
6/30/202353.02 53.23  (0.4 %)2024 Q1
3/31/2023-10.77 -23.2  (-115.38 %)2023 Q4
12/31/202265.47 122.25  (86.71 %)2023 Q3
9/30/202235.95 62.52  (73.93 %)2023 Q2
6/30/202243.5 70.15  (61.27 %)2023 Q1
3/31/202233.82 50.59  (49.58 %)2022 Q4
12/31/202185 73.99  (-12.96 %)2022 Q3
9/30/202196.43 21.17  (-78.05 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Taisho Pharmaceutical Holdings Co stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

99

👫 Social

73

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
22,353
Scope 2 - Indirect emissions from purchased energy
27,732
Scope 3 - Indirect emissions within the value chain
145,850
Total CO₂ emissions
50,085
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol✅
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Taisho Pharmaceutical Holdings Co list of shareholders

%
Name
Stocks
Change
Date
73.24145 % Otemon Co., Ltd.60,034,19460,034,1941/15/2024
4.75798 % Uehara Museum3,900,00009/30/2023
2.61445 % Uehara (Akira)2,143,00009/30/2023
2.01299 % Kajima Corp1,650,00009/30/2023
1.58001 % Nomura Asset Management Co., Ltd.1,295,095-7001/31/2024
1.53496 % The Vanguard Group, Inc.1,258,169-8,80012/31/2023
1.44325 % Taisei KK1,183,0001,183,0009/30/2023
0.93314 % Norges Bank Investment Management (NBIM)764,871-105,62012/31/2023
0.84509 % Dai Nippon Printing Co Ltd692,70003/31/2023
0.75650 % Nikko Asset Management Co., Ltd.620,0831,8001/31/2024
1
2
3
4
5
...
10

Taisho Pharmaceutical Holdings Co Executives and Management Board

Mr. Akira Uehara81
Taisho Pharmaceutical Holdings Co President, Chief Executive Officer, Chairman of Subsidiary, Representative Director (since 2011)
Compensation 77 M
Mr. Shigeru Uehara47
Taisho Pharmaceutical Holdings Co Vice President, CEO & President of Subsidiary, Director (since 2012)
Compensation 44 M
Mr. Osamu Kitatani64
Taisho Pharmaceutical Holdings Co CEO & President of Subsidiary, Director (since 2015)
Mr. Jun Kuroda66
Taisho Pharmaceutical Holdings Co Director (since 2013)
Mr. Ken Uehara45
Taisho Pharmaceutical Holdings Co Director (since 2011)
1
2

Taisho Pharmaceutical Holdings Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Mochida Pharmaceutical Stock
Mochida Pharmaceutical
SupplierCustomer0,850,780,780,600,100,70
Teijin Stock
Teijin
SupplierCustomer0,520,830,230,200,710,85
FUJIFILM Holdings Stock
FUJIFILM Holdings
SupplierCustomer0,510,560,170,080,57-0,43
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,500,55-0,65-0,50-0,43-0,54
Moberg Pharma Stock
Moberg Pharma
SupplierCustomer0,480,370,840,620,750,48
Yomeishu Seizo Stock
Yomeishu Seizo
SupplierCustomer0,370,050,820,620,860,84
Chugai Pharmaceutical Stock
Chugai Pharmaceutical
SupplierCustomer0,270,230,160,170,580,65
Procter & Gamble Stock
Procter & Gamble
SupplierCustomer0,230,47-0,67-0,37-0,73-0,75
MediciNova Stock
MediciNova
SupplierCustomer0,030,15-0,07-0,070,730,75
Mitsui Chemicals Stock
Mitsui Chemicals
SupplierCustomer0,02-0,030,070,050,750,03
1
2

Most common questions regarding Taisho Pharmaceutical Holdings Co

What values and corporate philosophy does Taisho Pharmaceutical Holdings Co represent?

Taisho Pharmaceutical Holdings Co Ltd represents a strong commitment to providing quality healthcare products and improving the well-being of individuals. Their corporate philosophy revolves around innovation, ethical practices, and customer satisfaction. With a focus on research and development, Taisho Pharmaceutical aims to create cutting-edge solutions that address various health concerns. The company's values include integrity, respect for diversity, and a dedication to social responsibility. By combining their expertise with a customer-centered approach, Taisho Pharmaceutical strives to make a positive impact on society through their pharmaceutical and healthcare offerings.

In which countries and regions is Taisho Pharmaceutical Holdings Co primarily present?

Taisho Pharmaceutical Holdings Co Ltd is primarily present in Japan.

What significant milestones has the company Taisho Pharmaceutical Holdings Co achieved?

Taisho Pharmaceutical Holdings Co Ltd has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Bristol-Myers Squibb's OTC drug business in 2009, expanding its product portfolio and market presence. In 2011, Taisho successfully launched its flagship product, Lipovitan D, a popular energy drink that quickly gained popularity in the Japanese market. Additionally, the company has consistently focused on research and development, leading to the introduction of innovative pharmaceutical products. Taisho Pharmaceutical Holdings Co Ltd continues to foster strategic partnerships and expand its global presence, making it a leading player in the healthcare industry.

What is the history and background of the company Taisho Pharmaceutical Holdings Co?

Taisho Pharmaceutical Holdings Co Ltd is a renowned pharmaceutical company with a rich history and notable background. Established in 1912, the company has been dedicated to improving healthcare and enhancing the well-being of individuals worldwide. With its headquarters in Tokyo, Japan, Taisho Pharmaceutical Holdings has expanded its operations to various countries, including the United States, China, and Southeast Asia. The company specializes in the research, development, manufacturing, and sales of a wide range of pharmaceutical products, including prescription drugs, OTC medications, and health-related products. Taisho Pharmaceutical Holdings Co Ltd has continuously strived for innovation and excellence, earning a reputation as a leading player in the global pharmaceutical industry.

Who are the main competitors of Taisho Pharmaceutical Holdings Co in the market?

The main competitors of Taisho Pharmaceutical Holdings Co Ltd in the market are Takeda Pharmaceutical Company Limited, Pfizer Inc., and GlaxoSmithKline plc.

In which industries is Taisho Pharmaceutical Holdings Co primarily active?

Taisho Pharmaceutical Holdings Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Taisho Pharmaceutical Holdings Co?

The business model of Taisho Pharmaceutical Holdings Co Ltd revolves around the development, manufacture, and sale of pharmaceutical products. As a leading Japanese pharmaceutical company, Taisho focuses on research and innovation to provide high-quality medications to improve people's health and well-being. The company specializes in therapeutic areas such as internal medicine, dermatology, and nutraceuticals. Taisho Pharmaceutical Holdings Co Ltd strives to establish a strong presence in both domestic and international markets, ensuring accessibility to their diverse range of healthcare products. With a dedication to advancing medical solutions, Taisho remains committed to addressing society's healthcare needs effectively.

What is the P/E ratio of Taisho Pharmaceutical Holdings Co 2024?

The Taisho Pharmaceutical Holdings Co P/E ratio is 58.85.

What is the P/S ratio of Taisho Pharmaceutical Holdings Co 2024?

The Taisho Pharmaceutical Holdings Co P/S ratio is 2.17.

What is the AlleAktien quality score of Taisho Pharmaceutical Holdings Co?

The AlleAktien quality score for Taisho Pharmaceutical Holdings Co is 2/10.

What is the revenue of Taisho Pharmaceutical Holdings Co 2024?

The expected Taisho Pharmaceutical Holdings Co revenue is 324.97 B JPY.

How high is the profit of Taisho Pharmaceutical Holdings Co 2024?

The expected Taisho Pharmaceutical Holdings Co profit is 11.97 B JPY.

What is the business model of Taisho Pharmaceutical Holdings Co

Taisho Pharmaceutical Holdings Co Ltd is a Japanese company active in the pharmaceutical, healthcare, and cosmetics sectors. The company was established in 1912 and has its headquarters in Tokyo, Japan. The business model of Taisho Pharmaceutical focuses on the development, production, and sale of innovative products aimed at improving people's health and well-being. The company operates three main business fields: pharmaceuticals, healthcare, and cosmetics. In the pharmaceutical business, Taisho Pharmaceutical manufactures and distributes medications used to treat diseases and ailments. The company has a wide range of medications for cardiovascular diseases, diabetes, pain and inflammation, as well as viral and bacterial infections. The company utilizes advanced technologies and places a major emphasis on research and development to consistently bring the best medication to the market. The healthcare business of Taisho Pharmaceutical includes a range of products aimed at maintaining people's health and well-being. The company offers dietary supplements, vitamins, sports and fitness products, as well as health monitoring devices. These products are sold through various distribution channels such as pharmacies, drugstores, and online shops. In the cosmetics field, Taisho Pharmaceutical offers a wide range of products including skincare, haircare, and makeup products. The company has developed its cosmetics products using its pharmaceutical technologies and research to create the best products. These products are sold both in the Japanese market and internationally. In conclusion, Taisho Pharmaceutical's business model is focused on innovation, research, and development. The company aims to improve people's health and well-being by developing innovative products that cater to customer needs. With its diverse range of products and services, Taisho Pharmaceutical successfully operates in the pharmaceutical, healthcare, and cosmetics industries and will continue to serve customers worldwide in the future.

What is the Taisho Pharmaceutical Holdings Co dividend?

Taisho Pharmaceutical Holdings Co pays a dividend of 100 JPY distributed over payouts per year.

How often does Taisho Pharmaceutical Holdings Co pay dividends?

The dividend cannot currently be calculated for Taisho Pharmaceutical Holdings Co or the company does not pay out a dividend.

What is the Taisho Pharmaceutical Holdings Co ISIN?

The ISIN of Taisho Pharmaceutical Holdings Co is JP3442850008.

What is the Taisho Pharmaceutical Holdings Co WKN?

The WKN of Taisho Pharmaceutical Holdings Co is A1JKG0.

What is the Taisho Pharmaceutical Holdings Co ticker?

The ticker of Taisho Pharmaceutical Holdings Co is 4581.T.

How much dividend does Taisho Pharmaceutical Holdings Co pay?

Over the past 12 months, Taisho Pharmaceutical Holdings Co paid a dividend of 100 JPY . This corresponds to a dividend yield of about 1.17 %. For the coming 12 months, Taisho Pharmaceutical Holdings Co is expected to pay a dividend of 100.72 JPY.

What is the dividend yield of Taisho Pharmaceutical Holdings Co?

The current dividend yield of Taisho Pharmaceutical Holdings Co is 1.17 %.

When does Taisho Pharmaceutical Holdings Co pay dividends?

Taisho Pharmaceutical Holdings Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Taisho Pharmaceutical Holdings Co?

Taisho Pharmaceutical Holdings Co paid dividends every year for the past 16 years.

What is the dividend of Taisho Pharmaceutical Holdings Co?

For the upcoming 12 months, dividends amounting to 100.72 JPY are expected. This corresponds to a dividend yield of 1.17 %.

In which sector is Taisho Pharmaceutical Holdings Co located?

Taisho Pharmaceutical Holdings Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taisho Pharmaceutical Holdings Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taisho Pharmaceutical Holdings Co from 6/1/2024 amounting to 50 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.

When did Taisho Pharmaceutical Holdings Co pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Taisho Pharmaceutical Holdings Co in the year 2023?

In the year 2023, Taisho Pharmaceutical Holdings Co distributed 100 JPY as dividends.

In which currency does Taisho Pharmaceutical Holdings Co pay out the dividend?

The dividends of Taisho Pharmaceutical Holdings Co are distributed in JPY.

All fundamentals about Taisho Pharmaceutical Holdings Co

Our stock analysis for Taisho Pharmaceutical Holdings Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taisho Pharmaceutical Holdings Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.